Memantine Hydrochloride Tablet
Product Images NDC 50090-6291

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-6291). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 01)

Chemical structure diagram of Memantine Hydrochloride showing its molecular shape with indicated functional groups including NH2 and HCl, and methyl substituents.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 02)

A line graph showing mean change from baseline in ADCS-ADL scores over 28 weeks of treatment for Memantine Hydrochloride (M.HCl) compared to placebo. The x-axis represents weeks of treatment (0, 4, 12, 28) and the y-axis shows mean change with clinical improvement and decline indicated. Memantine Hydrochloride shows a slower decline compared to placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 03)

A cumulative percentage of patients graph comparing the ADCS-ADL change from baseline for Memantine Hydrochloride (M.HCl) and placebo groups. The X-axis represents ADCS-ADL change values from 10 to -25, and the Y-axis shows cumulative percentages from 0 to 100. Memantine Hydrochloride shows a higher cumulative percentage of patients across the change range compared to placebo.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 04)

A line graph showing the mean (± SEM) change from baseline in SIB score over 28 weeks of treatment, comparing Memantine Hydrochloride (M.HCl) and placebo groups. The x-axis represents weeks of treatment, and the y-axis shows the change in SIB score with clinical improvement and decline markers.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 05)

A cumulative percentage of patients chart comparing SIB (Severe Impairment Battery) change from baseline. The graph has two lines: one marked with open circles labeled 'M. HCl' and the other with black squares labeled 'Placebo'. The x-axis shows SIB change from baseline with values ranging approximately from 15 to -30, and the y-axis shows the cumulative percentage of patients from 0 to 100.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 06)

A line graph showing the mean change from baseline in ADCS-ADL scores over 24 weeks of treatment. It compares two groups: one treated with Placebo/Donepezil and the other with Memantine Hydrochloride/Donepezil, with clinical improvement and decline indicated on the y-axis.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 07)

A cumulative percentage of patients graph showing ADCS-ADL change from baseline on the horizontal axis and cumulative percentage on the vertical axis. Two curves compare treatments: Placebo/Donepezil (black squares) and Memantine Hydrochloride (M. HCl)/Donepezil (open circles). The graph illustrates the distribution of patient responses to the treatments over a range of change values.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 08)

A line graph showing mean change from baseline in SIB score over 24 weeks of treatment comparing Placebo/Donepezil and Memantine Hydrochloride (M.HCl)/Donepezil. The y-axis represents mean change with error bars, indicating clinical improvement above zero and decline below zero. The x-axis shows weeks of treatment from 0 to 24. The Memantine Hydrochloride/Donepezil group shows an increase up to about week 12, then a gradual decline, while the Placebo/Donepezil group remains near baseline before decreasing after week 18.*

FDA Label Image

Memantine Hydrochloride Tablets (2dee57d8 27d7 481c B1c9 21375e258a1b 09)

A cumulative percentage of patients graph comparing SIB change from baseline between Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The x-axis shows SIB change from baseline, and the y-axis shows the cumulative percentage of patients, illustrating patient response distributions for the two treatment groups.*

FDA Label Image

Label Image (Lbl500906291)

Label for Memantine Hydrochloride 5 mg oral tablets by A-S Medication Solutions. The label displays the NDC 50090-6291, a lot number placeholder, storage instructions to store at 68 to 77 degrees Fahrenheit, and a quantity of 60 tablets. It also includes a QR code and mentions the dosage package insert.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.